Research programme: pain therapeutics - AstraZeneca

Drug Profile

Research programme: pain therapeutics - AstraZeneca

Alternative Names: AZ 09; AZ 11760788; AZ 12048189; AZ 12099548; AZ 1297442; AZ 599; AZD 7903; AZD 9335

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class 3-ring heterocyclic compounds; Indoles; Isoxazoles; Pyridines; Sulfonamides
  • Mechanism of Action Bradykinin B2 receptor antagonists; Cannabinoid receptor CB1 agonists; Nav1.7-voltage-gated-sodium-channel-inhibitors; Sodium channel antagonists; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Inflammatory pain; Neuropathic pain
  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-pain in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in Canada (IV, Infusion)
  • 31 Aug 2012 Pharmacodynamics data from a Preclinical trial in Neuropathic pain presented at the 14th World Congress on Pain (WCP-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top